Glenda M. Bishop

Glenda M. Bishop

Auto-generated profile, based on publicly available information

Glenda M. Bishop

Melbourne School of Population and Global Health, The University of Melbourne

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2007 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
RDRalf Dringen
Ralf Dringen
GBGlenda M. Bishop
Glenda M. Bishop
MKMaico Koeppe
Maico Koeppe
TDTheresa N. Dang
Theresa N. Dang
SRStephen R. Robinson
Stephen R. Robinson

2 December 2009 in Redox Report
Verified
Journal Article
Closed access
SRStephen R. Robinson
Stephen R. Robinson
TDTheresa N. Dang
Theresa N. Dang
RDRalf Dringen
Ralf Dringen
GBGlenda M. Bishop
Glenda M. Bishop
Hemorrhagic stroke is a common cause of permanent brain damage, with a significant amount of the damage occurring in the weeks following a stroke. This secondary damage is partly due to the toxic effects of hemin, a breakdown product of hemoglobin. The serum proteins hemopexin and albumin can bind hemin, but these natural defenses are insufficient to cope with the extremely high amounts of hemin (10 mM) that can potentially be liberated from hemoglobin in a hematoma. The present review discusses how hemin gets into brain cells, and examines the multiple routes through which hemin can be toxic. These include the release of redox-active iron, the depletion of cellular stores of NADPH and glutathione, the production of superoxide and hydroxyl radicals, and the peroxidation of membrane lipids. Important gaps are revealed in contemporary knowledge about the metabolism of hemin by brain cells, particularly regarding how hemin interacts with hydrogen peroxide. Strategies currently being developed for the reduction of hemin toxicity after hemorrhagic stroke include chelation therapy, antioxidant therapy and the modulation of heme oxygenase activity. Future strategies may be directed at preventing the uptake of hemin into brain cells to limit the opportunity for toxic interactions.

1 April 2007 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
GBGlenda M. Bishop
Glenda M. Bishop
RDRalf Dringen
Ralf Dringen
SRStephen R. Robinson
Stephen R. Robinson

1 November 2002 in Neurobiology of Aging
Verified
Journal Article
Closed access
SRStephen R. Robinson
Stephen R. Robinson
GBGlenda M. Bishop
Glenda M. Bishop

30 April 2010 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
GBGlenda M. Bishop
Glenda M. Bishop
TDTheresa N. Dang
Theresa N. Dang
RDRalf Dringen
Ralf Dringen
SRStephen R. Robinson
Stephen R. Robinson

1 October 2002 in Developmental Neuroscience
Verified
Journal Article
Closed access
PDF file
GBGlenda M. Bishop
Glenda M. Bishop
SRStephen R. Robinson
Stephen R. Robinson
QLQuan Liu
Quan Liu
George PerryGeorge Perry
George Perry
CACraig S. Atwood
Craig S. Atwood
MSMark A. Smith
Mark A. Smith
Brains from patients with Alzheimer disease (AD) show a disruption in the metabolism of iron, such that there is an accumulation of iron in senile plaques, and an altered distribution of iron transport and storage proteins. One of the earliest events in AD is the generation of oxidative stress, which may be related to the generation of free radicals by the excess iron that is observed in the disease. Iron has also been shown to mediate the in vitro toxicity of amyloid-β peptide, and the presence of iron in most in vitro systems could underlie the toxicity that is normally attributed to amyloid-β in these studies. In contrast, several recent studies have suggested that amyloid-β may decrease oxidative stress and decrease the toxicity of iron. Continued examination of the complex interactions that occur between iron and amyloid-β may assist in the elucidation of the mechanisms that underlie the neurodegeneration that leads to dementia in AD.